ASCENT-04: Sacituzumab Govitecan in Combination With Pembrolizumab as First Line Treatment for Patients With PD-L1 Expressing Triple Negative Breast Cancer
Condition: Breast Cancer
Sponsor: Gilead Sciences
Protocol GS-US-592-6173: A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1
Patients eligible for participation in this study will have locally advanced and inoperable or metastatic triple negative breast cancer without having received prior treatment in the advanced or metastatic setting. Eligible patients' cancer must be positive for expression of PD-L1.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.